1990至2019年全球204个国家ADHD的发病率、患病率与疾病负担:全球疾病负担研究数据及批判性再分析
本研究基于全球疾病负担(GBD)研究,报告1990至2019年全球及各国ADHD的发病率、患病率和负担。2019年全球年龄标化发病率为0.061%,患病率为1.13%,ADHD占全球精神障碍DALYs的0.8%,GBD将死亡率设为零。再分析显示2013年前儿童青少年患病率是GBD估计的两倍,且荟萃分析证据提示ADHD相关非自然原因死亡率显著增加,GBD可能低估了ADHD的患病率和负担。
要点
- 2019年全球ADHD年龄标化患病率为1.13%,发病率为0.061%,男性约为女性的2.5倍。
- 1990至2019年全球年龄标化患病率下降8.75%,发病率下降4.77%,美国增幅最大,芬兰降幅最大。
- 再分析显示儿童青少年ADHD患病率是GBD估计的两倍,且ADHD相关非自然原因死亡率显著增加。
核心结论
- GBD估计2019年全球ADHD年龄标化患病率为1.13%,发病率为0.061%,但再分析提示GBD可能低估了ADHD的患病率和负担。
研究设计与样本
- 基于全球疾病负担(GBD)研究,分析1990至2019年204个国家的ADHD发病率、患病率和DALYs数据,并进行批判性再分析。
主要发现
- 2019年全球年龄标化ADHD发病率为0.061%(95%UI=0.040-0.087),患病率为1.13%(95%UI=0.831-1.494)。
- ADHD占全球精神障碍DALYs的0.8%,GBD将ADHD相关死亡率设为零。
- 1990至2019年全球年龄标化患病率下降8.75%,发病率下降4.77%。
- 美国发病率、患病率和负担增幅最大,芬兰降幅最大。
- 1990至2019年男性发病率、患病率和DALYs约为女性的2.5倍。
关键数值与推荐
- 再分析2013年前数据显示儿童青少年ADHD患病率为5.41%(95%CI:4.67-6.15%),是GBD估计2.68%(95%CI:1.83-3.72%)的两倍。
- 再分析中低、中、高收入国家儿童青少年ADHD患病率无显著差异。
- 荟萃分析证据显示ADHD相关非自然原因死亡率显著增加。
临床怎么用
- 临床医生应知晓GBD可能低估ADHD患病率和负担,尤其儿童青少年人群。
- ADHD相关非自然原因死亡率增加提示需关注ADHD患者的风险评估与预防。
局限性
- GBD对无患病率数据国家采用数据填补估计,可能引入偏差。
- GBD将ADHD相关死亡率设为零,与荟萃分析证据不符,可能低估负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Data on incidence, prevalence and burden of ADHD are crucial for clinicians, patients, and stakeholders. We present the incidence, prevalence, and burden of ADHD globally and across countries from 1990 to 2019 from the Global Burden of Disease (GBD) study. We also: (1) calculated the ADHD prevalence based on data actually collected as opposed to the prevalence estimated by the GBD with data imputation for countries without prevalence data; (2) discussed the GBD estimated ADHD burden in the light of recent meta-analytic evidence on ADHD-related mortality. In 2019, GBD estimated global age-standardized incidence and prevalence of ADHD across the lifespan at 0.061% (95%UI = 0.040-0.087) and 1.13% (95%UI = 0.831-1.494), respectively. ADHD accounted for 0.8% of the global mental disorder DALYs, with mortality set at zero by the GBD. From 1990 to 2019 there was a decrease of -8.75% in the global age-standardized prevalence and of -4.77% in the global age-standardized incidence. The largest increase in incidence, prevalence, and burden from 1990 to 2019 was observed in the USA; the largest decrease occurred in Finland. Incidence, prevalence, and DALYs remained approximately 2.5 times higher in males than females from 1990 to 2019. Incidence peaked at age 5-9 years, and prevalence and DALYs at age 10-14 years. Our re-analysis of data prior to 2013 showed a prevalence in children/adolescents two-fold higher (5.41%, 95% CI: 4.67-6.15%) compared to the corresponding GBD estimated prevalence (2.68%, 1.83-3.72%), with no significant differences between low- and middle- and high-income countries. We also found meta-analytic evidence of significantly increased ADHD-related mortality due to unnatural causes. While it provides the most detailed evidence on temporal trends, as well as on geographic and sex variations in incidence, prevalence, and burden of ADHD, the GBD may have underestimated the ADHD prevalence and burden. Given the influence of the GBD on research and policies, methodological issues should be addressed in its future editions.
引用
- Cortese S, Song M, Farhat LC, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. Mol Psychiatry. 2023. PMID: 37684322. doi:10.1038/s41380-023-02228-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。